Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ESMO18 Previews’

We’ll have “boots on the ground” for the 2018 Congress of the European Society for Medical Oncology (Twitter: #ESMO18) that starts out of the gate on Friday in Munich.

The Fall cancer conference season is in swing…

Our conference coverage is not only about what data we think matters, particularly in the fast-moving world of immuno-oncology, but more importantly, why it matters.

Next up in our ESMO18 Previews, we take a closer look at renal cancer, an area that received some attention in Madrid last year and is likely to receive renewed focus again.

We also include a look at the broader RCC landscape in terms of US physician prescribing habits (i.e. KOL and Community oncologists), including some trend data to explore the impact of the nivo/ipi combination and cabozantinib data, as well as excerpts from an expert interview we conducted with Dr Awny Farajallah, Head of U.S. Medical at Bristol Myers Squibb.

Finally, we also highlight some key abstracts to watch out for in renal cell carcinoma (RCC) that are expected to be presented at ESMO18 and explore their relevance.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ESMO18 is rapidly approaching with only a week to go before the conference kicks off in Munich this year.

Munich

So far in our Preview series we have highlighted what to watch out for in the late breakers, neoantigens, as well as the oral talks and poster discussions.

Now it’s time to turn our focus on the nuggets or gems that can be gleaned from the poster halls – there’s always a few pleasant surprises in store. There are small and large pharma/biotech companies included in this latest list on a wide range of therapeutics and tumour types.

There are also some interesting emerging trends, as well as hints of what might happen with some future phase 3 readouts that could catch a few people by surprise.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

The ESMO 2018 Congress is fast approaching (Twitter hashtag: #ESMO18) and BSB will be in Munich diligently providing on-site coverage for subscribers.

Old Town Hall, Munich

Over 2000 abstracts will be presented on the latest cancer immunotherapy research, biomarkers and translational research.

We’ll have plenty to write about, plus we hope to record some interviews that we may excerpt on the Novel Targets Podcast, so stay tuned for that too.

In our third preview, we highlight what we think are key abstracts to watch out for in Munich outside of the late breakers (those are covered here) in terms of how they advance our thinking and move the field forward, or could impact clinical practice.

Here we go – ESMO18 Preview 3 Top 10 Oral Abstracts to watch out for…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Times Square, New York

New York – Every now and then you go to a cancer conference and instead of hearing the expected standard talk that is repeated time and time again for a season or so, you are delighted with a more engaging and uninhibited approach that captivates and informs on the latest state of the art progress.

It also means that more than the presenter realises is perhaps shared.  That’s very good news indeed for intrepid science writers and anyone who cares to listen or read.

The research mentioned in today’s post falls in the engaged and delighted category…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

 

 

 

The 2018 European Society for Medical Oncology (#ESMO18) Congress will take place in Munich from October 19 to 23 and it’s a meeting we’re looking forward to covering on Biotech Strategy Blog.

We’ll have “boots on the ground” in Munich.

ESMO 2018 Banner

One of the highlights of the ESMO Congress are the late-breaking abstracts, for which ESMO keeps open multiple slots in their program. As a result, the meeting provides an opportunity to hear some of the latest data.

The titles and times for most of the late-breakers have now been published in the on line program, so what can we look forward to at ESMO18?

In our first Preview we’ve highlighted several to watch out for, why we think they are noteworthy and in many cases, what the potential significance might be in a broader context.

Please note that the abstracts for late breakers aren’t typically available until the start of the congress session in which they will be presented or if they’re in the press program, until after the press briefing, so we’re not discussing any data in this post.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!